Lantern Pharma is FAIRLY VALUED at 19.21 per share with modest projections ahead. Lantern Pharma appears to be somewhat reliable, given 1 month investment horizon. Lantern Pharma has Sharpe Ratio of 0.0936, which conveys that the firm had 0.0936% of return per unit of risk over the last month. Our standpoint towards estimating the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. By analyzing Lantern Pharma technical indicators you can presently evaluate if the expected return of 0.71% is justified by implied risk. Please exercise Lantern Pharma Downside Deviation of 5.12, mean deviation of 3.83, and Risk Adjusted Performance of 0.0281 to check out if our risk estimates are consistent with your expectations.